ZYME

Thematic Snapshot – Antibody Drug Conjugates (ADCs) Biotech M&A has been an intriguing area recently, as outlined in the Quarterly Brief, and one potential deal...

Immunomedic (IMMU) a notable deal in Biotech at a value of $21B and coming at a sizable 108% premium from Gilead (GILD) with M&A in...

ZymeWorks (ZYME) notable insider on 1/27 from director Troy Cox of 7,500 shares at $46.50, a nearly $350,000 investment. This is the first open market buy...